MetiMedi Pharmaceutical and Eden Nature Partner for Health Solutions Based on 'METI-101'

MetiMedi Pharmaceutical and Eden Nature are embarking on a collaborative venture to develop innovative health solutions centered around 'METI-101,' a substance derived from cell metabolism research. This partnership signifies a strategic move to leverage the distinct strengths of both companies in the burgeoning health and wellness market.

The collaboration builds upon a technology transfer agreement established last year. For the current year, the companies plan to advance the project through raw material development and product planning. The core objective is to merge MetiMedi Pharmaceutical's robust research and development (R&D) capabilities with Eden Nature's established expertise in the health food sector and its extensive distribution network.

'METI-101' is a novel research substance developed through in-depth studies of cellular metabolic processes and the biological environment. It has garnered significant international attention, with patent applications filed in approximately 50 countries. MetiMedi Pharmaceutical possesses foundational research technologies related to the regulation of cellular metabolic environments and is actively exploring applications across various health management fields.

By integrating MetiMedi's scientific research with Eden Nature's product development and market access capabilities, the companies aim to create scientifically validated and trustworthy health management solutions. This initiative is poised to tap into the growing demand for evidence-based health products, positioning both companies for growth in a competitive landscape.

“

This collaboration aims to jointly develop scientific and reliable health management solutions by combining MetiMedi Pharmaceutical's R&D capabilities with Eden Nature's health food and distribution know-how.